POEMs

Patient-Oriented Evidence That Matters

Guideline for Chronic Diarrhea: Screening for IBD and Celiac Disease Is In, Screening for Ova and Parasites Is Out

 

Am Fam Physician. 2020 Mar 1;101(5):310-311.

Clinical Question

What workup should be considered for patients with chronic diarrhea?

Bottom Line

Although an algorithm to guide the workup is not offered, the American Gastroenterological Association suggests the following tests for patients with chronic diarrhea (i.e., watery diarrhea for at least four weeks): fecal calprotectin or fecal lactoferrin to screen for inflammatory bowel disease (IBD), and testing for giardiasis, celiac disease, and bile acid diarrhea. They do not recommend screening for ova and parasites unless the patient has come from a high-risk area. They also recommend against using erythrocyte sedimentation rate (ESR) and C-reactive protein to screen for IBD. (Level of Evidence = 5)

Synopsis

This guideline was developed by a team comprising two gastroenterologists, a primary care physician, and a methodologist, but no patient representative. They performed a systematic review and graded the level of evidence using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology. One team member reported financial relationships with companies that make diagnostic or treatment products for gastrointestinal disorders. In patients with chronic diarrhea, the group suggests screening for IBD using fecal calprotectin or fecal lactoferrin, but not ESR or C-reactive protein (conditional recommendation based on low-quality evidence). They also recommend testing for Giardia (strong recommendation based on high-quality evidence), but recommend against testing for ova or other parasites unless the patient is from or has traveled to a high-risk area (conditional recommendation based on low-quality evidence). They also suggest testing for celiac disease (strong recommendation based on moderate-quality evidence) and testing for bile acid diarrhea by assay or by an empiric trial of a bile acid binder (conditional recommendation based on low-quality evidence). The group does not recommend a specific order of testing.

Study design: Practice guideline


Editor's Note: Dr. Shaughnessy is an assistant medical editor for AFP.

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see https://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to https://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

 

 

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Jun 1, 2020

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article